JPS62292716A - Ointment base - Google Patents
Ointment baseInfo
- Publication number
- JPS62292716A JPS62292716A JP61135569A JP13556986A JPS62292716A JP S62292716 A JPS62292716 A JP S62292716A JP 61135569 A JP61135569 A JP 61135569A JP 13556986 A JP13556986 A JP 13556986A JP S62292716 A JPS62292716 A JP S62292716A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- ointment
- ointment base
- drug
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003883 ointment base Substances 0.000 title claims abstract description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 235000011187 glycerol Nutrition 0.000 claims abstract description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 4
- 239000003349 gelling agent Substances 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 11
- 239000002674 ointment Substances 0.000 abstract description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 6
- 239000003470 adrenal cortex hormone Substances 0.000 abstract description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 238000001879 gelation Methods 0.000 abstract description 3
- 239000003589 local anesthetic agent Substances 0.000 abstract description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 abstract description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 abstract description 2
- 239000000661 sodium alginate Substances 0.000 abstract description 2
- 235000010413 sodium alginate Nutrition 0.000 abstract description 2
- 229940005550 sodium alginate Drugs 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract 2
- 229920002125 Sokalan® Polymers 0.000 abstract 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 abstract 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 14
- 238000004026 adhesive bonding Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 4
- 229960001067 hydrocortisone acetate Drugs 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- -1 carboxyvinyl Chemical group 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010033546 Pallor Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950010121 ufenamate Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
３、発明の詳細な説明
〔産業上の利用分野〕
本発明は軟膏基剤、更に詳しくは、難溶性薬物をよく溶
解し、薬物の放出性、吸収性を向上させて当該薬物の効
果を充分に発揮させることができると共に、使用感のよ
い水溶性軟膏基剤に関する。[Detailed Description of the Invention] 3. Detailed Description of the Invention [Field of Industrial Application] The present invention provides an ointment base, more specifically, an ointment base that dissolves poorly soluble drugs and improves drug release and absorption. The present invention relates to a water-soluble ointment base that can fully exhibit the effects of the drug and is comfortable to use.
難溶性薬物を外用に使用する場合、その治療効果は、薬
物の基剤への溶解性と相関するとされており、例えば副
腎皮質ホルモン含有軟膏は、上腕部看白性試験において
、完全溶解型のものは非溶解型に比較して約５培の効力
があることが報告されている。When a poorly soluble drug is used externally, its therapeutic effect is said to be correlated with the solubility of the drug in the base.For example, an ointment containing adrenocortical hormone was found to be completely soluble in an upper arm visibility test. It has been reported that the non-dissolved version is about 5 times more effective than the non-dissolved version.
しかし、従来、難溶性薬物、特に副腎皮質ホルモンを完
全に溶解する軟膏基剤は提供されておらず、当該薬物の
効果を完全に発現させることは困難であると考えられて
いたｏｆた、一方従来の軟膏基剤はワセリン等の油脂性
のものであるため、使用部位がべとつくと共に、衣類等
に付着するという欠点があった。However, to date, no ointment base has been provided that completely dissolves poorly soluble drugs, especially adrenocortical hormones, and it has been thought that it is difficult to fully express the effects of the drug. Since conventional ointment bases are oil-based such as petrolatum, they have the disadvantage of being sticky on the application site and adhering to clothing and the like.
斯かる実情において、本発明者は鋭意研究を行った結果
、上記問題点を克服した軟膏基剤を得ることに成功した
。Under these circumstances, the inventors of the present invention conducted intensive research and succeeded in obtaining an ointment base that overcomes the above-mentioned problems.
すなわち、本発明は、プロピレングリコール５〜３０ｆ
ｆｉ１％１．１ｅｌＪ工チレングリコール５〜５０重！
俤、グル化剤０．１〜５重量優、グリセリンｌＯ〜４０
重量俤及びアルカリ剤０．１〜３重量％を含有する軟膏
基剤を提供するものである。That is, the present invention provides propylene glycol 5-30f
fi1%1.1elJ engineered tylene glycol 5-50 weight!
迤, Gluing agent 0.1-5% by weight, Glycerin 10-40
The present invention provides an ointment base containing 0.1 to 3% by weight of an alkaline agent.
ゾロピレングリコールは一般の軟膏基剤として使用され
ているものであるが、一般に高含量で用いると皮膚刺激
があると考えられている。しかし５通常の外用剤の使用
形態において、基剤中３０重量％（以下、単に優と表示
する）以下の場合には重篤な刺激性は認められない。従
って、本発明においては、プロピレングリコールは全組
成の５〜３０％、好ましくは５〜２０％になるように配
合される。Zoropylene glycol is commonly used as an ointment base, but is generally thought to cause skin irritation when used in high concentrations. However, in the usual usage form of external preparations, serious irritation is not observed when the amount is 30% by weight or less (hereinafter simply referred to as "excellent") in the base. Therefore, in the present invention, propylene glycol is blended in an amount of 5 to 30%, preferably 5 to 20% of the total composition.
ポリエチレングリコールは、凝固点及び水に対する溶解
性の点から、平均分子量２００〜６００、特に２００〜
４００のもの（破りエチレングリコール２００〜４００
）が好ましい。またその配合量は、難溶性薬物の溶解性
の点からすれば多い程よいが、あまり多いと基剤系が不
安定となるので、これらを考慮し、全組成の５〜５０％
、好ましくは１０〜３０％配合される。Polyethylene glycol has an average molecular weight of 200 to 600, particularly 200 to 600, in terms of freezing point and water solubility.
400 (broken ethylene glycol 200-400)
) is preferred. In addition, from the viewpoint of solubility of the poorly soluble drug, the larger the amount is, the better, but if it is too large, the base system will become unstable.
, preferably 10 to 30%.
グル化剤としては、例えば、アクリル酸の重合した酸性
高分子であるカルボキシビニル？リマー、メチルセルロ
ース、カルボキシメチルセルロース、ヒドロキシプロピ
ルセルロース、ヒドロキシプロピルメチルセルロース、
アルギン酸ナトリウム等が挙げられる。この中でも、粘
度が適当でしかも温度変化による粘度の変動が少なく、
また経日安定性がよい等の点から、カルゴキシビニル？
リフ−＃９４０又は＃９４１が特に好ましい。このグル
化剤の配合量によってグル化状態及び粘度が異なり、ま
た軟膏の粘度は添加される難溶性薬物の種類によっても
異なるので、グル化剤の配合量はその都度決定されるが
、通常全組成の０．１〜５％配合される。Examples of gluing agents include carboxyvinyl, which is an acidic polymer made from polymerized acrylic acid. Rimmer, methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose,
Examples include sodium alginate. Among these, the viscosity is suitable and there is little fluctuation in viscosity due to temperature changes.
Also, since it has good stability over time, cargoxyvinyl?
Rif-#940 or #941 is particularly preferred. The gluing state and viscosity vary depending on the amount of the gluing agent, and the viscosity of the ointment also differs depending on the type of poorly soluble drug added, so the amount of the gluing agent is determined on a case-by-case basis. It is added in an amount of 0.1 to 5% of the composition.
グリセリンは保湿剤として冷加されるものであり、ゲル
化剤によるゲル化への影響を考慮し、局方グリセリンを
使用するのが好ましい。その配合量は、ゲル化剤及び難
溶性薬物の溶解性の点から、１０〜４０％、好ましくは
１０〜３０％である。Glycerin is a moisturizing agent that is cooled, and in consideration of the influence of gelling agents on gelation, it is preferable to use pharmacopoeial glycerin. The blending amount is 10 to 40%, preferably 10 to 30% from the viewpoint of solubility of the gelling agent and the poorly soluble drug.
アルカリ剤としては、モノエタノールアミン、ジェタノ
ールアミン、トリエタノールアミン、水酸化ナトリウム
、炭酸ナトリウム等が使用される。このアルカリ剤はグ
ル化剤を中和するために使用されるものであり、その配
合量は全組成のＯ，１〜３％が好ましい。As the alkaline agent, monoethanolamine, jetanolamine, triethanolamine, sodium hydroxide, sodium carbonate, etc. are used. This alkaline agent is used to neutralize the gluing agent, and its amount is preferably 1 to 3% of the total composition.
本発明の軟膏基剤に配合して効果の同上がみられる難溶
性薬物としては、例えば、ヒドロコルチゾン、酢酸ヒド
ロコルチゾン、ゾレトニゾロン、酢酸ゾレドニゾロン等
の則腎皮質ホルモン；アミノ安息香酸エチル、塩酸テト
ラカイン、塩酸ゾロカイン、塩酸ゾプカイン、塩酸リド
カイン等の局所麻酔剤；インドメタシン、ブフエキサマ
ツク、フルフェナム酸ブチル、ビタミンＡ等の鎮痛、鎮
痒、収斂、消炎剤が挙げられる。この中でも、抗炎症剤
の副腎皮質ホルモンと局所麻酔剤の塩酸ゾプカインを併
用して本発明軟膏基剤に配合して得られる軟膏は特に優
れた効果’ｋＷする。これらの薬物の配合量は、一般の
外用剤への配合量に準ずればよいが、従来の外用剤への
配合量より少ない量で高い効果が得られる。Examples of sparingly soluble drugs that can be combined with the ointment base of the present invention and exhibit the same effects as above include renal cortical hormones such as hydrocortisone, hydrocortisone acetate, zoletnisolone, and zolednisolone acetate; ethyl aminobenzoate, tetracaine hydrochloride, and hydrochloric acid. Local anesthetics such as zorocaine, zopcaine hydrochloride, and lidocaine hydrochloride; analgesic, antipruritic, astringent, and antiinflammatory agents such as indomethacin, bufexamac, butyl flufenamate, and vitamin A. Among these, an ointment obtained by combining adrenocortical hormone, an anti-inflammatory agent, and zopcaine hydrochloride, a local anesthetic, into the ointment base of the present invention has particularly excellent effects. The amount of these drugs to be blended may be the same as that in general external preparations, but high effects can be obtained with a smaller amount than in conventional external preparations.
本発明の軟膏基剤２用いて軟膏を調表するには、例えば
、難溶性薬物を７″ロビレングリコール及ヒ、ｊｅｌＪ
エチレングリコールの混合液に溶解させ、これにゲル化
剤の水膨潤液及びグリセリンを添加し、最後にアルカリ
剤を加えてグル化させる方法によって行われる。面この
際粘度調節剤としてぼりビニルピロリドンを添加するこ
ともできる。To prepare an ointment using the ointment base 2 of the present invention, for example, a sparingly soluble drug may be mixed with 7'' robylene glycol and gel J.
This is carried out by dissolving in a mixed solution of ethylene glycol, adding thereto a water-swelling solution of a gelling agent and glycerin, and finally adding an alkaline agent to cause gluing. At this time, vinylpyrrolidone can also be added as a viscosity modifier.
次に実施例を挙げて説明する。 Next, an example will be given and explained.
実施例１゜
下記組成の軟膏金調裂し、ヒト上腕部の、Ｑソチテスト
により薬物（酢酸ヒドロコルチゾン）の効果を評価した
。Example 1 An ointment having the following composition was cut into pieces, and the effect of the drug (hydrocortisone acetate) was evaluated using the QSochi test on human upper arms.
（１） 組成
本発明軟膏：
酢酸ヒドロコルチゾン ０．１ Ｃ重１１ノロピ
レングリコール １５．Ｏ
？ジエチレングリコール２００ ４５．０カルボキシビ
ニル？リマー＊０．５
グリセリン １０．０
トリエタノールアミン １．０
精製水 ２８，４
（注）＊カーボ？−ル＃９４１（ミツヤ化工社製）比較
軟１１Ｆ：
酢酸ヒドロコルチゾン ０．１（重量％）ワセリ
ン ７０゜９スノＱン６０
５．０ラノリン ２４．
０
（２）評価方法
７９ツチテストは軟膏閉鎖貼付１７時間後１、Ｑツチを
除去し、貼付部位全水洗いし、除去１時間後及び３時間
後に貼付部の蒼白度？相対的に数値化（０：不変、１：
境界線が不明瞭であるが中心が蒼白、２：境界線が明瞭
な蒼白、３：境界面が明らかで強い蒼白）した０尚値は
１０名の平均値で示した。(1) Composition Ointment of the present invention: Hydrocortisone acetate 0.1 C-11 noropyrene glycol 15. O? Diethylene glycol 200 45.0 carboxyvinyl? Rimmer *0.5 Glycerin 10.0 Triethanolamine 1.0 Purified water 28.4 (Note) *Carbo? -L #941 (manufactured by Mitsuya Kako Co., Ltd.) Comparative soft 11F: Hydrocortisone acetate 0.1 (wt%) Vaseline 70°9 Suno Q-on 60
5.0 Lanolin 24.
0 (2) Evaluation method 79 Tsuchi test: 17 hours after application of ointment, Q Tsuchi is removed, the entire application area is washed with water, and 1 hour and 3 hours after removal, the pallor level of the application area is evaluated. Relatively quantified (0: unchanged, 1:
The score of 0 was expressed as the average value of 10 patients.
（３）結果
第１表（蒼白度〕
以上の試験から明らかな如く、本発明の軟膏基剤を使用
して調製した本発明状ｆは比較軟膏に比較し約５倍の効
果を示した０
実施例２゜
下記組成の軟−１！Ｆｆ！：調表し、使用試ｔｉ！ｌヲ
したところ、効力、使用感ともにすぐれたものであった
。(3) Results Table 1 (pallor level) As is clear from the above tests, the present invention f prepared using the ointment base of the present invention showed about 5 times the effect compared to the comparative ointment. Example 2 Soft-1!Ff! of the following composition: When prepared and tested in use, it was found to be excellent in both efficacy and feeling of use.
組成：
デレドニゾロン ０．０５（重量％）塩酸ゾ
ブカイン ０．２０
プロピレングリコール ２０．００
ポリエチレングリコール２００ ３５．００＊
カルボキシビニル？リマ−０，８０
グリセリン ２５．００
ゾエタノールアミン ０．５０
精裂水 １８．４５
（注）＊カーボ？−ル＃９４０（ミツヤ化工社製）〔発
明の効果〕
本発明軟膏基剤は難溶性薬物をよく溶解し、薬物の効果
を完全に発現させることができるので、少量の薬物の配
合によって高い効果を得ることができると共に、これに
よって調製された軟膏はべとつきがなく使用感が優れて
いるという特長’に！する。Composition: Delednisolone 0.05 (wt%) Zobucaine hydrochloride 0.20 Propylene glycol 20.00 Polyethylene glycol 200 35.00* Carboxyvinyl? Limer 0.80 Glycerin 25.00 Zoethanolamine 0.50 Semena water 18.45 (Note) *Carbo? -L #940 (manufactured by Mitsuya Kako Co., Ltd.) [Effects of the invention] The ointment base of the present invention can dissolve poorly soluble drugs well and fully express the effects of the drug, so it is highly effective with a small amount of drug. In addition to this, the ointment prepared using this method has the advantage of not being sticky and having an excellent feeling of use! do.
以上that's all
Claims (1)
ングリコール５〜５０重量％、ゲル化剤０．１〜５重量
％、グリセリン１０〜４０重量％及びアルカリ剤０．１
〜３重量％を含有する軟膏基剤。1. Propylene glycol 5-30% by weight, polyethylene glycol 5-50% by weight, gelling agent 0.1-5% by weight, glycerin 10-40% by weight, and alkali agent 0.1
Ointment base containing ~3% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61135569A JPS62292716A (en) | 1986-06-11 | 1986-06-11 | Ointment base |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61135569A JPS62292716A (en) | 1986-06-11 | 1986-06-11 | Ointment base |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62292716A true JPS62292716A (en) | 1987-12-19 |
| JPH0511093B2 JPH0511093B2 (en) | 1993-02-12 |
Family
ID=15154878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61135569A Granted JPS62292716A (en) | 1986-06-11 | 1986-06-11 | Ointment base |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62292716A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2302808A (en) * | 1995-07-04 | 1997-02-05 | Surtech Int Ltd | Propylene glycol with low potency corticosteroids for topical treatment of the scalp |
| JP2002531526A (en) * | 1998-12-04 | 2002-09-24 | ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド | Topical skin preparation in anhydrous state |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59122420A (en) * | 1982-12-28 | 1984-07-14 | Otsuka Pharmaceut Factory Inc | Local ointment |
-
1986
- 1986-06-11 JP JP61135569A patent/JPS62292716A/en active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59122420A (en) * | 1982-12-28 | 1984-07-14 | Otsuka Pharmaceut Factory Inc | Local ointment |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2302808A (en) * | 1995-07-04 | 1997-02-05 | Surtech Int Ltd | Propylene glycol with low potency corticosteroids for topical treatment of the scalp |
| JP2002531526A (en) * | 1998-12-04 | 2002-09-24 | ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド | Topical skin preparation in anhydrous state |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0511093B2 (en) | 1993-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gatot et al. | Effects of sodium hypochlorite on soft tissues after its inadvertent injection beyond the root apex | |
| JPS6135167B2 (en) | ||
| JP2003505422A5 (en) | ||
| CA2620374A1 (en) | Pharmaceutical compositions for the treatment of inner ear disorders | |
| PT1210934E (en) | Pharmaceutical carrier preparation applicable to mucosal surfaces | |
| PT1920773E (en) | Thalidomide and dexamethasone for the treatment of tumors | |
| BR122014001142B8 (en) | process of producing a colonic purgative tablet formulation for oral administration | |
| MX2007001512A (en) | Adhesive composition. | |
| JPH0794394B2 (en) | Anti-inflammatory analgesic external patch | |
| JPH0338250B2 (en) | ||
| JP4195178B2 (en) | Anti-inflammatory analgesic topical | |
| JPS62292716A (en) | Ointment base | |
| JP6099044B2 (en) | Medical composition | |
| JP4648518B2 (en) | Patch containing 4-biphenylacetic acid | |
| US20240148648A1 (en) | Sustained release thermosetting gels comprising anesthetic drugs and the methods of making the same | |
| JPH08333245A (en) | Ibuprofen suspension liquid | |
| JP3472442B2 (en) | Formulation for repairing damaged skin | |
| JP3031990B2 (en) | Anti-inflammatory analgesic cream composition | |
| JP2005187328A (en) | Antipyretic and analgesic composition comprising ibuprofen and drug for common cold | |
| US20220296719A1 (en) | Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same | |
| JP2006232724A (en) | Gel composition and method for producing the same | |
| JPH07223938A (en) | Bath for patch | |
| JPH0231052B2 (en) | ||
| JP2009537200A (en) | Adhesive solution for application to the skin | |
| ES2225301T3 (en) | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL ADMINISTRATION IN THE ORAL CAVITY OF NON-STEROID ANTI-INFLAMMATORY PHARMACES USEFUL FOR ANTI-INFLAMMATORY AND STOMATOLOGICAL, MOUTH AND ORAL CAVITY THERAPIES. |